NoBlood

Cancer. 2006 Jul 1;107(1):136-40

Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage.

Kalmadi S, Tiu R, Lowe C, Jin T, Kalaycio M.

Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, Ohio 44122, USA. kalmads@ccf.org

BACKGROUND: Epsilon aminocaproic acid (EACA) is an antifibrinolytic drug that has been used to control hemorrhage by stabilizing the thrombus. It has been used in thrombocytopenic patients largely on an empiric basis. METHODS: Concerns regarding side effects have limited the use of this drug. The authors reviewed their experience with EACA at the Cleveland Clinic Foundation from 1997 to 2003. RESULTS: Of 77 patients with thrombocytopenic hemorrhage, 51 (66%) patients achieved a complete response and 13 (17%) patients achieved a partial response, resulting in a decrease in platelet and red blood cell transfusions. Adverse effects were manageable in this set of patients with severe underlying disease. CONCLUSIONS: Based on this experience, EACA may be a valuable adjunctive therapy in the treatment of patients with thrombocytopenic hemorrhage. Copyright 2006 American Cancer Society.

Entrez PubMed

__________________
Sharon Grant
Editorial Team